Skip to content

Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy

Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04138979
Enrollment
80
Registered
2019-10-25
Start date
2019-09-12
Completion date
2020-10-15
Last updated
2019-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microbiota

Keywords

gut microbiota, 16S rRNA gene, breast cancer chemotherapy

Brief summary

To date, few studies have addressed the link between gut microbiota and breast cancer chemotherapy, and previous studies have only provided a link between the gut and breast cancer.

Detailed description

To date, few studies have addressed the link between gut microbiota and breast cancer chemotherapy, and previous studies have only provided a link between the gut and breast cancer.At present, studies on the interaction mechanism between intestinal flora and breast cancer mainly focus on two aspects: first, intestinal flora affects the occurrence and progress of breast cancer by affecting estrogen metabolism;Second, intestinal flora can influence the occurrence and treatment of breast cancer by affecting the regulation of the immune system.However, the specific types (or groups) of bacteria that promote the occurrence, development and mechanism of breast cancer still need to be further studied.In addition, since most of the current clinical studies on microorganisms and breast cancer are small sample studies, the accuracy of their conclusions remains to be studied.

Interventions

DRUGcyclophosphamide

First use of chemotherapy after breast cancer

Sponsors

First Affiliated Hospital of Harbin Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 18 to 65 years * First use of chemotherapy after breast cancer

Exclusion criteria

* Pregnancy * Lactation * Cigarette smoking * Alcohol addiction * Hypertension * Diabetes mellitus * Lipid dysregulation * BMI \> 27 * Recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine * History of disease with an autoimmune component, such as MS, rheumatoid arthritis, IBS, or IBD * History of malignancy or any gastrointestinal tract surgery

Design outcomes

Primary

MeasureTime frameDescription
Transcriptional changes in gut microbiotabaseline,1 day,7 day,14 days,22 days,29 days,36 days,44days,51days,58days,66days,73days,80daysThe microbiota measured by 16S rRNA gene

Countries

China

Contacts

Primary ContactYunwei Wei, doctor
hydwyw11@hotmail.com+86-0451-85553099

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026